Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: a subanalysis of the EMIT-AF/VTE study

Table 1 Baseline patient demographics and clinical characteristics

	Major surgery patients^a (n = 250)	Nonmajor surgery patients^a (n = 461)	P-value
Age^b, years, mean ± SD	73.1 ± 8.8	74.8 ± 9.7	0.023
<65	37 (14.8)	55 (11.9)
65 to < 75	103 (41.2)	146 (31.7)
≥75	110 (44.0)	260 (56.4)
Sex
Male	153 (61.2)	276 (59.9)	0.729
Female	97 (38.8)	185 (40.1)
Weight, kg, mean ± SD	75.6 ± 16.4	75.9 ± 16.2	0.808
BMI, kg/m², mean ± SD	26.7 ± 4.4	27.0 ± 5.0	0.415
Atrial fibrillation	229 (91.6)	437 (94.8)	0.095
CrCL, mL/min, mean ± SD	70.7 ± 25.9	66.3 ± 27.8	0.052
≤50	52 (20.8)	115 (24.9)
Hypertension	186 (74.4)	350 (75.9)	0.653
Diabetes mellitus	49 (19.6)	132 (28.6)	0.008
Dyslipidaemia	108 (43.2)	182 (39.5)	0.335
Coronary heart disease	41 (16.4)	86 (18.7)	0.454
Valvular heart disease	46 (18.4)	81 (17.6)	0.783
Congestive heart failure	33 (13.2)	64 (13.9)	0.800
HAS-BLED score, mean ± SD	2.0 ± 1.0	1.8 ± 1.1	0.134
CHA₂DS₂-VASc score, mean ± SD	3.5 ± 1.5	3.6 ± 1.5	0.476
Edoxaban dose
30 mg/day	86 (34.4)	158 (34.3)	0.973
60 mg/day	162 (64.8)	302 (65.5)
Other	2 (0.8)	1 (0.2)
Antiplatelet agents	38 (15.2)	52 (11.3)	0.133

Data are shown as n (%) unless otherwise noted. P-values were calculated using Fisher’s exact test
BMI Body mass index, CHA₂DS₂-VASc Congestive heart failure, Hypertension, Age ≥ 75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74 years, and Sex category, CrCL Creatinine clearance, HAS-BLED Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalised ratio, Elderly, Drugs/alcohol concomitantly, n Number of patients, SD Standard deviation
^aBaseline data for patients who underwent both major and nonmajor surgery on the same day were counted once in the major surgery group
^bAge at the time of enrolment

ISSN: 1477-9560